Ameliorating effects of mirtazapine on visceral hypersensitivity in rats with neonatal colon sensitivity

Yin, Jieyun; Wang, W.; Winston, John H.; Zhang, R.; Chen, J. D Z

doi:10.1111/j.1365-2982.2010.01526.x

Cited by 17 publications

(23 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients with severe gastroparesis unresponsive to the conventional prokinetic treatment, refractory nausea and vomiting that persisted for over 7 mo were improved dramatically within a few days of once-daily mirtazapine dosing (29). In a previous study, we observed improvement of gastric emptying with mirtazapine in colonic sensitized "IBS-like" rats (42). In the present canine study, we found that mirtazapine improved gastric emptying, gastric accommodation, and colon transit; this was different from what was reported in a clinical study in which mirtazapine showed no effects on gastric emptying in healthy volunteers (7).…”

Section: Discussionmentioning

confidence: 96%

“…It is known that many IBS patients display visceral hypersensitivity during colorectal distention (26,30,33). In an earlier study we reported improvement on visceral hypersensitivity with the administration of mirtazapine in colonic sensitized rats (42); however, its effect on the colonic transit was not investigated. In the present study, we found that mirtazapine accelerated colonic transit in normal dogs.…”

Section: Discussionmentioning

confidence: 96%

“…In the present study, mirtazapine blocked the rectal distention-induced inhibitory effects on gastric motility. In a previous study, mirtazapine was found to reduce rectal distention-induced gastric hypersensitivity (42).…”

Section: Discussionmentioning

confidence: 99%

“…It increases the release of norepinephrine (NE) and serotonin (5-hydroxytryptamine, 5-HT) by blocking presynaptic ␣ 2 -adrenergic receptors (11,16). Recently, it was reported that mirtazapine reduced visceral hypersensitivity and accelerated liquid gastric emptying in rats with neonatal colon sensitivity (42). Clinic case report showed that mirtazapine was effective in treating severe gastroparesis unresponsive to the conventional prokinetic treatment (29); in a patient with diabetic gastroparesis who is recalcitrant to first-line treatment, mirtazapine improved gastroparetic symptoms (20).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Prokinetic effects of mirtazapine on gastrointestinal transit

Yin

Song

Lei

et al. 2014

American Journal of Physiology-Gastrointestinal and Liver Physi

View full text Add to dashboard Cite

Mirtazapine is a noradrenergic and specific serotonergic antidepressant. The aim of this study was to investigate the effects of mirtazapine on gastrointestinal motility in dogs, including solid gastric emptying, antral and small intestinal contractions, and small intestinal and colonic transit. Six dogs were implanted with two cannulas located at the duodenum and the ascending colon; another six dogs were implanted with gastric cannula 6 cm proximal to the pylorus. Mirtazapine 45 mg was administered orally 90 min before the study. We found that 1) Mirtazapine accelerated gastric emptying during the entire 3 h in normal dogs (P Ͻ 0.04) and accelerated delayed gastric emptying induced by rectal distention (P Ͻ 0.04). 2) Mirtazapine restored impaired gastric tone and accommodation induced by rectal distention (P Ͻ 0.05). 3) No significant changes were noted in small intestinal contractions or transit with mirtazapine (P Ͼ 0

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Prokinetic effects of mirtazapine on gastrointestinal transit

Yin

Song

Lei

et al. 2014

American Journal of Physiology-Gastrointestinal and Liver Physi

View full text Add to dashboard Cite

show abstract

“…Therefore, we should pay more attention to FD patients with weight loss and their associated psychological disorders in clinical practice. On the basis of animal studies of antidepressant mirtazapine on the cachexia model and gastrointestinal function [22,23,24], a series of animal and clinical studies (Registration number: ChiCTR-TRC-13003161) are now carrying on to demonstration antidepressant mirtazapine as an effective treatment to manage FD patients with weight loss.…”

Section: Discussionmentioning

confidence: 99%

The Clinical-Psychological Features of Functional Dyspepsia Patients with Weight Loss: A Multi-Center Study from China

Liu

Jia²,

Lei³

et al. 2015

Digestion

View full text Add to dashboard Cite

Aims: To investigate the clinical features, appetite, quality of life (QOL), and their associated psychological factors of functional dyspepsia (FD) patients with weight loss. Methods: For a multicenter study, FD patients were recruited and divided into two groups according to the degree of weight changes during the previous 12 months or less with the onset of dyspepsia symptoms: Group A (≥5%) and Group B (<5%). Patients were evaluated based on the Nepean dyspepsia index (NDI), appetite questionnaire, Hamilton Rating Scale of Anxiety/Depression (HAMA/HAMD). Results: The body mass index in Group A was lower than in Group B, while, the frequency of physician visits in Group A was higher than in Group B. There were no differences in the total scores of NDI-symptom checklist or the items of intensity and bothersomeness between them (p > 0.05), but the frequency item for Group A was significantly higher than Group B (p = 0.035). The incidence of anxiety or depression, the proportion of poor or very poor appetite for Group A was higher than those for Group B (p < 0.05). Subscale scores of the NDI-QOL for Group A were significantly lower than those for Group B (p < 0.05). Conclusions: FD patients with weight loss have lower BMI, more frequent physician visits, higher psychological disorders, poorer appetite and QoL.

show abstract

Centrally Targeted Pharmacotherapy for Chronic Abdominal Pain: Understanding and Management

Törnblom

Drossman

2016

Gastrointestinal Pharmacology

View full text Add to dashboard Cite

Chronic abdominal pain has a widespread impact on the individual and the society. Identifying and explaining mechanisms of importance for the pain experience within a biopsychosocial context are central in order to select treatment that has a chance for symptom reduction. With current knowledge of brain-gut interactions, chronic abdominal pain, which mostly appears in functional gastrointestinal disorders, to a large extent involves pain mechanisms residing within the brain. As such, the use of centrally targeted pharmacotherapy as an effective treatment option is obvious in a selected number of patients. The antidepressants are most common, but also other classes of medications can be used, either alone or in combination. The latter option refers to when there is insufficient effect of one drug alone or side effects limiting dosage, and when combined in lower doses, certain drugs give rise to augmentation effects. This chapter outlines basic mechanisms of importance for the understanding of chronic abdominal pain and the pharmacologic treatment options.

show abstract

Ameliorating effects of mirtazapine on visceral hypersensitivity in rats with neonatal colon sensitivity

Cited by 17 publications

References 41 publications

Prokinetic effects of mirtazapine on gastrointestinal transit

Prokinetic effects of mirtazapine on gastrointestinal transit

The Clinical-Psychological Features of Functional Dyspepsia Patients with Weight Loss: A Multi-Center Study from China

Centrally Targeted Pharmacotherapy for Chronic Abdominal Pain: Understanding and Management

Contact Info

Product

Resources

About